These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 18303479)

  • 1. The role of angiogenesis inhibitors in prostate cancer.
    Aragon-Ching JB; Dahut WL
    Cancer J; 2008; 14(1):20-5. PubMed ID: 18303479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VEGF inhibitors and prostate cancer therapy.
    Aragon-Ching JB; Dahut WL
    Curr Mol Pharmacol; 2009 Jun; 2(2):161-8. PubMed ID: 19617926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-angiogenesis in prostate cancer: knocked down but not out.
    Bilusic M; Wong YN
    Asian J Androl; 2014; 16(3):372-7. PubMed ID: 24759579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug insight: VEGF as a therapeutic target for breast cancer.
    Schneider BP; Sledge GW
    Nat Clin Pract Oncol; 2007 Mar; 4(3):181-9. PubMed ID: 17327858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer.
    Merino M; Pinto A; González R; Espinosa E
    Eur J Cancer; 2011 Aug; 47(12):1846-51. PubMed ID: 21600762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel agents for the treatment of advanced kidney cancer.
    Cooney MM; Remick SC; Vogelzang NJ
    Clin Adv Hematol Oncol; 2004 Oct; 2(10):664-70. PubMed ID: 16163253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting angiogenesis as a promising modality for the treatment of prostate cancer.
    Lin J; Kelly WK
    Urol Clin North Am; 2012 Nov; 39(4):547-60. PubMed ID: 23084530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From bevacizumab to tasquinimod: angiogenesis as a therapeutic target in prostate cancer.
    Schweizer MT; Carducci MA
    Cancer J; 2013; 19(1):99-106. PubMed ID: 23337763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In pursuit of new anti-angiogenic therapies for cancer treatment.
    Cai J; Han S; Qing R; Liao D; Law B; Boulton ME
    Front Biosci (Landmark Ed); 2011 Jan; 16(3):803-14. PubMed ID: 21196204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on angiogenesis inhibitors.
    Zakarija A; Soff G
    Curr Opin Oncol; 2005 Nov; 17(6):578-83. PubMed ID: 16224236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer.
    Collins TS; Hurwitz HI
    Semin Oncol; 2005 Feb; 32(1):61-8. PubMed ID: 15726507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value and effectiveness of angiogenesis inhibitors for colorectal cancer.
    Venook AP
    Clin Adv Hematol Oncol; 2015 Sep; 13(9):561-3. PubMed ID: 26452184
    [No Abstract]   [Full Text] [Related]  

  • 13. [Interests in angiogenesis inhibitor drugs approved for the treatment of cancers].
    Bennis Y; Guillet B; Curti C; Pisano P
    Therapie; 2010; 65(2):95-105. PubMed ID: 20478241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical experience with antiangiogenic therapy in leukemia.
    Wellbrock J; Fiedler W
    Curr Cancer Drug Targets; 2011 Nov; 11(9):1053-68. PubMed ID: 21999626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiogenesis and anti-angiogenic therapy in prostate cancer.
    Mukherji D; Temraz S; Wehbe D; Shamseddine A
    Crit Rev Oncol Hematol; 2013 Aug; 87(2):122-31. PubMed ID: 23375349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiogenesis as a therapeutic target in urothelial carcinoma.
    Pinto A; Redondo A; Zamora P; Castelo B; Espinosa E
    Anticancer Drugs; 2010 Nov; 21(10):890-6. PubMed ID: 20729712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antiangionic drugs in soft tissue sarcoma].
    Salas S; Huynh T; Deville JL; Duffaud F
    Bull Cancer; 2010 Jun; 97(6):701-5. PubMed ID: 20483703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted agents and systemic therapy in hepatocellular carcinoma.
    Ang C; O'Reilly EM; Abou-Alfa GK
    Recent Results Cancer Res; 2013; 190():225-46. PubMed ID: 22941024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer.
    Quesada AR; Medina MA; Alba E
    Bioessays; 2007 Nov; 29(11):1159-68. PubMed ID: 17935210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Tumor vasculature as a therapeutic target in non-small cell lung cancer].
    Döme B; Magyar M
    Magy Onkol; 2008 Sep; 52(3):247-59. PubMed ID: 18845495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.